Phase 2 Stomach Cancer Trial, Recruiting NCT06005493 Sponsor: AstraZeneca Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT06005493
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older at the time of signing the consent form
  • You have been confirmed through a tissue test (biopsy) to have a type of cancer called adenocarcinoma, located in the stomach, the junction between the stomach and food pipe, the food pipe (esophagus), or the pancreas
  • You have at least one tumour that can be measured on a scan, according to standard criteria
  • Your tumour has tested positive for a protein called CLDN18.2, confirmed by a specific lab test
  • You are generally well enough to carry out light activity and care for yourself (a doctor will assess this using a standard scale)
  • You are expected to live for at least 12 weeks
  • Your organs (such as kidneys, liver) and bone marrow are working well enough, confirmed by blood tests taken within 28 days before starting the trial
  • You are using contraception in line with local guidelines, as required by the trial
  • You have already received at least one previous treatment (such as chemotherapy) for your cancer after it spread or could not be removed by surgery

Who may not be able to join:

  • You still have significant side effects (grade 2 or higher) from a previous cancer treatment that have not fully resolved
  • You previously had a severe reaction called cytokine release syndrome or a serious brain/nervous system reaction from certain immune-based cancer therapies (T cell engagers or CAR-T cell therapy)
  • You have a history of a serious immune system condition called hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) (confirm with trial site)
  • You currently have, or have had in the past 3 years, an autoimmune or inflammatory condition (where your immune system attacks your own body)
  • You have had cancer spread to your brain or certain brain-related conditions within the past 3 months
  • You have certain active infections, including HIV, active hepatitis B or C, uncontrolled Epstein-Barr virus (EBV), or an uncontrolled fungal, bacterial, or other serious infection
  • You have certain heart conditions, as defined by the trial (confirm with trial site)
  • You have had a blood clot in a vein or artery within the past 3 months
  • You need to take long-term medicines that suppress your immune system
  • You are currently taking blood-thinning (anticoagulant) medicines at full treatment doses

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
11 July 2023
Est. completion
16 July 2027

Where this trial is recruiting

🇨🇳 China 🇫🇷 France 🇯🇵 Japan 🇳🇱 Netherlands 🇰🇷 South Korea 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

The number of patients with adverse events; The number of patients with adverse events of special interest; The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.; The number of patients with serious adverse events; Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov